Enzon Pharmaceuticals 8-K: Shareholder Vote Update

TL;DR

Enzon Pharma held a shareholder vote on Sept 26. Details to follow.

AI Summary

Enzon Pharmaceuticals, Inc. filed an 8-K on October 1, 2024, reporting on matters submitted to a vote of security holders on September 26, 2024. The filing details the company's corporate structure and its principal executive offices located at 20 Commerce Drive, Suite 135, Cranford, New Jersey.

Why It Matters

This filing indicates that Enzon Pharmaceuticals held a shareholder vote, which could signal significant corporate actions or changes in governance that may impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K reporting a shareholder vote, with no immediate financial or operational risks disclosed.

Key Players & Entities

• ENZON PHARMACEUTICALS, INC. (company) — Registrant
• September 26, 2024 (date) — Date of earliest event reported
• October 1, 2024 (date) — Date of report
• 20 Commerce Drive, Suite 135, Cranford, New Jersey (location) — Principal executive offices

FAQ

Filing Documents

• tm2425136d1_8k.htm (8-K) — 38KB
• 0001104659-24-104951.txt ( ) — 201KB
• enzn-20240926.xsd (EX-101.SCH) — 3KB
• enzn-20240926_lab.xml (EX-101.LAB) — 33KB
• enzn-20240926_pre.xml (EX-101.PRE) — 22KB
• tm2425136d1_8k_htm.xml (XML) — 3KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. The 2024 annual meeting of stockholders (the " Annual Meeting ") of the Company was held on September 26, 2024. At the Annual Meeting, the Company's stockholders voted on the following matters as described in the Company's proxy materials: (1) the election of three directors, each for a one-year term expiring at the Company's next annual meeting of stockholders and until such director's successor is elected and qualified, (2) the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, (3) the approval, on an advisory basis, of the compensation of the Company's named executive officer, and (4) to ratify an amendment to the Rights Agreement by and between us and Continental Stock Transfer & Trust Company, to extend the Final Expiration Date (as defined in the Rights Agreement) to the close of business on March 31, 2025. A total of 58,112,406 shares of common stock were present or represented by proxy at the Annual Meeting, representing approximately 78% of the total shares of common stock entitled to vote. As such, a quorum was present. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management's solicitation. 1. Election of Directors - The Company's stockholders elected each of the following individuals as a director of the Company, as set forth below: Nominee Votes For Votes Against Abstentions Broker Non-Votes Jordan Bleznick 41,175,630 2,051,893 13,351 14,871,532 Jaffery (Jay) A. Firestone 41,188,207 2,039,316 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENZON PHARMACEUTICALS, INC. (Registrant) Date: October 1, 2024 By: /s/ Richard L. Feinstein Name: Richard L. Feinstein Title: Chief Executive Officer, Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR